Varicella Zoster Infection Treatment Market Report and Forecast 2025-2034
Description
The varicella zoster infection treatment market was valued at USD 1.83 Billion in 2024, driven by the rising incidence of herpes zoster across the 8 major markets. The market is anticipated to grow at a CAGR of 7.60% during the forecast period of 2025-2034, with the values likely to reach USD 3.81 Billion by 2034.
Varicella Zoster Infection Treatment Market Overview
The varicella-zoster virus, also called human herpesvirus 3, leads to chickenpox in kids and shingles in adults. The treatment for current Varicella Zoster infection consists of antiviral medications such as acyclovir, valacyclovir, or famciclovir, in addition to pain relievers and corticosteroids. There are preventive vaccines for Varicella Zoster Infection that is due to the varicella-zoster virus and causes both chickenpox and shingles. The advances in technology and the rising understanding of viral latency and reactivation are driving the growth of the market.
Varicella Zoster Infection Treatment Market Growth Drivers
Increasing Disease Prevalence and Surveillance Advancements
The higher awareness and prevalence of new virus variants are driving the demand for varicella zoster infection treatment. For instance, in September 2023, the discovery of the Clade 9 variant in India which is common in countries like Germany, the UK, and the US, highlighted the need for improved surveillance and treatment options. Such new strains are expected to increase demand for treatment and drive market growth during the forecast period.
Varicella Zoster Infection Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Increasing Emphasis on Vaccination
There is an increased focus on managing infection rates with vaccination. For instance, The Centers for Disease Control and Prevention recommended two doses of Shingrix for adults over 50 and those with weakened immune systems, aiming to prevent Herpes zoster and complications.
Emergence of New Viral Strains
The discovery of the Clade 9 variant of the varicella-zoster virus in India indicated an increasing importance in the treatment due to the emergence of new viral strains. With the emergence of new strains, healthcare professionals are increasing continuous monitoring and investigation which are essential for adjusting to these changes.
Rising Need to Reduce the Risk of Severe Complications
The market is witnessing an increased focus on preventing severe complications associated with varicella zoster infections, such as postherpetic neuralgia and encephalitis. With the aging population and individuals with weakened immune systems being more vulnerable to these conditions, the treatment market is expected to witness significant growth in the forecast period.
Growing Need for Specialized Treatments
The increasing demand for specialized treatment such as therapies tailored to the unique needs of high-risk populations, such as the immunocompromised individuals is a major market trend. The focus on specialized antiviral treatments, personalized dosages, and a deeper understanding is contributing to the development of more effective and safer therapies.
Varicella Zoster Infection Treatment Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment:
Segmentation Based on Treatment to Witness Substantial Growth
Based on the treatment, the market is segmented into vaccines, medication, and others. Vaccines are expected to dominate the market in the forecast period as they play a crucial role in the treatment by offering preventative defense against chickenpox. Antiviral medications address ongoing infections, while vaccines focus on prevention to achieve herd immunity and lower healthcare expenses.
Varicella Zoster Infection Treatment Market Analysis by Region
The market is divided into regions such as the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India. The United States is expected to lead the market share due to growing cases of chickenpox and shingles among older adults and immunocompromised individuals. Additionally, the region focuses on vaccination and progress in antiviral treatments such as Acyclovir and Shingrix are crucial in preventing these infections.
Leading Players in the Varicella Zoster Infection Treatment Market
The key features of the market report comprise patent analysis, clinical trial analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Merck & Co., Inc.
Merck & Co., Inc., an American pharmaceutical company based in New Jersey, offers VARIVAX® for varicella zoster infection treatment. The vaccine protects against chickenpox through active immunization in individuals aged 12 months and older.
GSK plc
GlaxoSmithKline, a British pharmaceutical company, launched the Shingrix vaccine in India in April 2023 for treating shingles caused by the varicella-zoster virus. The vaccine provides over 90% efficacy and long-lasting protection.
Pfizer Inc.
Pfizer Inc., an American pharmaceutical corporation headquartered in Manhattan, New York City, is a major market player. The company is collaborating with BioNTech to develop an mRNA-based shingles vaccine.
F. Hoffmann-La Roche AG
Roche, a Swiss multinational healthcare company, offers the UC-TIB-HSV/VZV real-time PCR kit for diagnosing herpes simplex virus and varicella zoster virus infections. This diagnostic tool aids in accurate detection and management of infections in transplant and immunocompromised patients.
Other key players in the market include Sanofi S.A., Novartis AG, Viatris Inc., and Takeda Pharmaceutical Company.
Key Questions Answered in the Varicella Zoster Infection Treatment Market Report
Varicella Zoster Infection Treatment Market Overview
The varicella-zoster virus, also called human herpesvirus 3, leads to chickenpox in kids and shingles in adults. The treatment for current Varicella Zoster infection consists of antiviral medications such as acyclovir, valacyclovir, or famciclovir, in addition to pain relievers and corticosteroids. There are preventive vaccines for Varicella Zoster Infection that is due to the varicella-zoster virus and causes both chickenpox and shingles. The advances in technology and the rising understanding of viral latency and reactivation are driving the growth of the market.
Varicella Zoster Infection Treatment Market Growth Drivers
Increasing Disease Prevalence and Surveillance Advancements
The higher awareness and prevalence of new virus variants are driving the demand for varicella zoster infection treatment. For instance, in September 2023, the discovery of the Clade 9 variant in India which is common in countries like Germany, the UK, and the US, highlighted the need for improved surveillance and treatment options. Such new strains are expected to increase demand for treatment and drive market growth during the forecast period.
Varicella Zoster Infection Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Increasing Emphasis on Vaccination
There is an increased focus on managing infection rates with vaccination. For instance, The Centers for Disease Control and Prevention recommended two doses of Shingrix for adults over 50 and those with weakened immune systems, aiming to prevent Herpes zoster and complications.
Emergence of New Viral Strains
The discovery of the Clade 9 variant of the varicella-zoster virus in India indicated an increasing importance in the treatment due to the emergence of new viral strains. With the emergence of new strains, healthcare professionals are increasing continuous monitoring and investigation which are essential for adjusting to these changes.
Rising Need to Reduce the Risk of Severe Complications
The market is witnessing an increased focus on preventing severe complications associated with varicella zoster infections, such as postherpetic neuralgia and encephalitis. With the aging population and individuals with weakened immune systems being more vulnerable to these conditions, the treatment market is expected to witness significant growth in the forecast period.
Growing Need for Specialized Treatments
The increasing demand for specialized treatment such as therapies tailored to the unique needs of high-risk populations, such as the immunocompromised individuals is a major market trend. The focus on specialized antiviral treatments, personalized dosages, and a deeper understanding is contributing to the development of more effective and safer therapies.
Varicella Zoster Infection Treatment Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment:
- Vaccines
- Medication
- Others
- Oral
- Topical
- Parenteral
- Hospitals
- Homecare
- Specialty Clinics
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Segmentation Based on Treatment to Witness Substantial Growth
Based on the treatment, the market is segmented into vaccines, medication, and others. Vaccines are expected to dominate the market in the forecast period as they play a crucial role in the treatment by offering preventative defense against chickenpox. Antiviral medications address ongoing infections, while vaccines focus on prevention to achieve herd immunity and lower healthcare expenses.
Varicella Zoster Infection Treatment Market Analysis by Region
The market is divided into regions such as the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and India. The United States is expected to lead the market share due to growing cases of chickenpox and shingles among older adults and immunocompromised individuals. Additionally, the region focuses on vaccination and progress in antiviral treatments such as Acyclovir and Shingrix are crucial in preventing these infections.
Leading Players in the Varicella Zoster Infection Treatment Market
The key features of the market report comprise patent analysis, clinical trial analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Merck & Co., Inc.
Merck & Co., Inc., an American pharmaceutical company based in New Jersey, offers VARIVAX® for varicella zoster infection treatment. The vaccine protects against chickenpox through active immunization in individuals aged 12 months and older.
GSK plc
GlaxoSmithKline, a British pharmaceutical company, launched the Shingrix vaccine in India in April 2023 for treating shingles caused by the varicella-zoster virus. The vaccine provides over 90% efficacy and long-lasting protection.
Pfizer Inc.
Pfizer Inc., an American pharmaceutical corporation headquartered in Manhattan, New York City, is a major market player. The company is collaborating with BioNTech to develop an mRNA-based shingles vaccine.
F. Hoffmann-La Roche AG
Roche, a Swiss multinational healthcare company, offers the UC-TIB-HSV/VZV real-time PCR kit for diagnosing herpes simplex virus and varicella zoster virus infections. This diagnostic tool aids in accurate detection and management of infections in transplant and immunocompromised patients.
Other key players in the market include Sanofi S.A., Novartis AG, Viatris Inc., and Takeda Pharmaceutical Company.
Key Questions Answered in the Varicella Zoster Infection Treatment Market Report
- What was the varicella zoster infection treatment market value in 2024?
- What is the varicella zoster infection treatment market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on treatment?
- What is the market segmentation based on the route of administration?
- What is the market breakup based on the end user?
- What major factors aid the demand for varicella zoster infection treatment?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Who are the key players involved in the varicella zoster infection treatment market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Varicella Zoster Infection Treatment Market Overview – 8 Major Markets
- 3.1 Varicella Zoster Infection Treatment Market Historical Value (2018-2024)
- 3.2 Varicella Zoster Infection Treatment Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Varicella Zoster Infection Treatment Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Varicella Zoster Infection Treatment Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.2 Prevalence, by Country
- 7.2.1 United States
- 7.2.2 United Kingdom
- 7.2.3 EU4
- 7.2.4 India
- 7.2.5 Japan
- 7.3 Diagnosed Cases, by Country
- 7.3.1 United States
- 7.3.2 United Kingdom
- 7.3.3 EU4
- 7.3.4 India
- 7.3.5 Japan
- 7.4 Treatment Seeking Rate, by Country
- 7.4.1 United States
- 7.4.2 United Kingdom
- 7.4.3 EU4
- 7.4.4 India
- 7.4.5 Japan
- 8 Varicella Zoster Infection Treatment Market Landscape – 8 Major Markets
- 8.1 Varicella Zoster Infection Treatment Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Varicella Zoster Infection Treatment Market: Product Landscape
- 8.2.1 Analysis by Treatment
- 8.2.2 Analysis by Route of Administration
- 9 Varicella Zoster Infection Treatment Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Varicella Zoster Infection Treatment Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Varicella Zoster Infection Treatment Market Segmentation (218-2034) - 8 Major Markets
- 12.1 Varicella Zoster Infection Treatment Market (2018-2034) by Treatment
- 12.1.1 Market Overview
- 12.1.2 Vaccines
- 12.1.3 Medication
- 12.1.4 Others
- 12.2 Varicella Zoster Infection Treatment Market (2018-2034) by Route of Administration
- 12.2.1 Market Overview
- 12.2.2 Oral
- 12.2.3 Topical
- 12.2.4 Parenteral
- 12.3 Varicella Zoster Infection Treatment Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospitals
- 12.3.3 Homecare
- 12.3.4 Specialty Clinics
- 12.3.5 Others
- 12.4 Varicella Zoster Infection Treatment Market (2018-2034) by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Varicella Zoster Infection Treatment Market (218-2034)
- 13.1 United States Varicella Zoster Infection Treatment Market (2018-2034) by Treatment
- 13.1.1 Market Overview
- 13.1.2 Vaccines
- 13.1.3 Medication
- 13.1.4 Others
- 13.2 United States Varicella Zoster Infection Treatment Market (2018-2034) by Route of Administration
- 13.2.1 Market Overview
- 13.2.2 Oral
- 13.2.3 Topical
- 13.2.4 Parenteral
- 13.3 United States Varicella Zoster Infection Treatment Market (2018-2034) by End User
- 13.3.1 Market Overview
- 13.3.2 Hospitals
- 13.3.3 Homecare
- 13.3.4 Specialty Clinics
- 13.3.5 Others
- 14 EU-4 and United Kingdom Varicella Zoster Infection Treatment Market (218-2034)
- 14.1 EU-4 and United Kingdom Varicella Zoster Infection Treatment Market (2018-2034) by Treatment
- 14.1.1 Market Overview
- 14.1.2 Vaccines
- 14.1.3 Medication
- 14.1.4 Others
- 14.2 EU-4 and United Kingdom Varicella Zoster Infection Treatment Market (2018-2034) by Route of Administration
- 14.2.1 Market Overview
- 14.2.2 Oral
- 14.2.3 Topical
- 14.2.4 Parenteral
- 14.3 EU-4 and United Kingdom Varicella Zoster Infection Treatment Market (2018-2034) by End User
- 14.3.1 Market Overview
- 14.3.2 Hospitals
- 14.3.3 Homecare
- 14.3.4 Specialty Clinics
- 14.3.5 Others
- 15 Japan Varicella Zoster Infection Treatment Market (218-2034)
- 15.1 Japan Varicella Zoster Infection Treatment Market (2018-2034) by Treatment
- 15.1.1 Market Overview
- 15.1.2 Vaccines
- 15.1.3 Medication
- 15.1.4 Others
- 15.2 Japan Varicella Zoster Infection Treatment Market (2018-2034) by Route of Administration
- 15.2.1 Market Overview
- 15.2.2 Oral
- 15.2.3 Topical
- 15.2.4 Parenteral
- 15.3 Japan Varicella Zoster Infection Treatment Market (2018-2034) by End User
- 15.3.1 Market Overview
- 15.3.2 Hospitals
- 15.3.3 Homecare
- 15.3.4 Specialty Clinics
- 15.3.5 Others
- 16 India Varicella Zoster Infection Treatment Market (218-2034)
- 16.1 India Varicella Zoster Infection Treatment Market (2018-2034) by Treatment
- 16.1.1 Market Overview
- 16.1.2 Vaccines
- 16.1.3 Medication
- 16.1.4 Others
- 16.2 India Varicella Zoster Infection Treatment Market (2018-2034) by Route of Administration
- 16.2.1 Market Overview
- 16.2.2 Oral
- 16.2.3 Topical
- 16.2.4 Parenteral
- 16.3 India Varicella Zoster Infection Treatment Market (2018-2034) by End User
- 16.3.1 Market Overview
- 16.3.2 Hospitals
- 16.3.3 Homecare
- 16.3.4 Specialty Clinics
- 16.3.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Application
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Drug Class of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Drug Class of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share Analysis, By Region (Top 5 Companies)
- 23.2 Merck & Co., Inc.
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Developments
- 23.2.5 Certifications
- 23.3 GSK plc
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Developments
- 23.3.5 Certifications
- 23.4 Sanofi S.A.
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Developments
- 23.4.5 Certifications
- 23.5 Pfizer Inc.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Developments
- 23.5.5 Certifications
- 23.6 Novartis AG
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Developments
- 23.6.5 Certifications
- 23.7 F. Hoffmann-La Roche AG
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Developments
- 23.7.5 Certifications
- 23.8 Viatris Inc.
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Developments
- 23.8.5 Certifications
- 23.9 Takeda Pharmaceutical Company
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Company News and Developments
- 23.9.5 Certifications
- 24 Varicella Zoster Infection Treatment Market - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
